Compare IRMD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRMD | ABUS |
|---|---|---|
| Founded | 1992 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 910.4M | 848.1M |
| IPO Year | 2014 | N/A |
| Metric | IRMD | ABUS |
|---|---|---|
| Price | $96.26 | $4.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $72.00 | $5.00 |
| AVG Volume (30 Days) | 74.4K | ★ 1.1M |
| Earning Date | 11-03-2025 | 11-13-2025 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | ★ 13.00 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $80,511,268.00 | $14,606,000.00 |
| Revenue This Year | $15.17 | $125.30 |
| Revenue Next Year | $10.15 | N/A |
| P/E Ratio | $58.33 | ★ N/A |
| Revenue Growth | 12.91 | ★ 116.64 |
| 52 Week Low | $47.48 | $2.71 |
| 52 Week High | $98.44 | $5.10 |
| Indicator | IRMD | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 75.36 | 60.87 |
| Support Level | $94.94 | $4.43 |
| Resistance Level | $98.44 | $4.63 |
| Average True Range (ATR) | 2.15 | 0.19 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 80.50 | 89.66 |
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.